[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100420486":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":37,"locations":47,"responsibleParty":64,"collaborators":67,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":41,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":41,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":50,"whyStopped":41,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Dong-A University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"De-escalation strategy","EXPERIMENTAL","PCI \\~ 1 month: ticagrelor 90 mg twice daily + aspirin 100 mg once daily\n\n1 \\~ 3 months: ticagrelor 60 mg twice daily + aspirin 100 mg once daily\n\n3 \\~ 12 months: ticagrelor 60 mg twice daily",[13],"Drug: De-escalation strategy",{"label":15,"type":16,"description":17,"interventionNames":18},"Conventional strategy","ACTIVE_COMPARATOR","PCI \\~ 12 months: ticagrelor 90 mg twice daily + aspirin 100 mg once daily",[19],"Drug: Conventional strategy",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","De-escalation strategy indicates conventional DAPT (ticagrelor 90 mg twice daily + aspirin 100 mg once daily) for 1 month, followed by de-escalation DAPT (ticagrelor 60 mg twice daily + aspirin 100 mg once daily) between 1 and 3 months. Between 3 and 12 months, patients will be treated with ticagrelor monotherapy (ticagrelor 60 mg twice daily).",[9],[26],"Ticagrelor 60 mg, aspirin early discontinuation",{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Conventional stratetgy indicates conventional DAPT including ticagrelor 90 mg twice daily and aspirin 100 mg once daily during 12 months.",[15],[31],"Ticagrelor 90 mg, DAPT",[33],{"name":34,"affiliation":35,"role":36},"Moo Hyun Kim, MD, PhD","Dong-A University Hospital, Busan, Republic of Korea","PRINCIPAL_INVESTIGATOR",[38,43],{"name":34,"role":39,"phone":40,"phoneExt":41,"email":42},"CONTACT","+82-51-240-2976",null,"kimmh@dau.ac.kr",{"name":44,"role":39,"phone":45,"phoneExt":41,"email":46},"Young-Hoon Jeong, MD, PhD","+82-2-2610-6795","goodoctor@naver.com",[48],{"facility":49,"status":50,"city":51,"state":41,"zip":52,"country":53,"countryCode":41,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"DongA University Hospital","RECRUITING","Busan","602-715","South Korea",{"type":55,"coordinates":56},"Point",[57,58],129.03004,35.10168,{"lat":58,"lon":57},[61,63],{"name":62,"role":39,"phone":40,"phoneExt":41,"email":42},"Moo Hyun Kim, M.D.",{"name":62,"role":36,"phone":41,"phoneExt":41,"email":41},{"type":36,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":41,"oldOrganization":41},"Moo Hyun Kim","Professor, Deptartment of Cardiology, Dong-A University Hospital",[68,71],{"name":69,"class":70},"Biotronik SE & Co. KG","INDUSTRY",{"name":72,"class":70},"Samjin Pharmaceutical Co., Ltd.","100420486","phase-4-ticagrelor-de-escalation-strategy-in-ami-patients-100420486",false,"NCT04755387","Ticagrelor De-escalation Strategy in AMI Patients","EASTYLE (DE-escAlation Strategy for Optimal Ticagrelor Therapy in Acute MYocardiaL Infarction PatiEnts, Prospective, Multicenter, Randomized) Trial","Inclusion Criteria:\n\n* Diagnosis with acute myocardial infarction.\n* Age ≥19 year-old\n* Successful PCI with ultrathin bioresorbable polymer sirolimus-eluting stents (Orsiro; Biotronik AG).\n* Provision of informed consent.\n\nExclusion Criteria:\n\n* Any prior event of hemorrhagic stroke or ICH.\n* Active bleeding (e.g., GI bleeding, ICH) or high-risk of serious bleeding.\n* Bleeding diathesis or coagulopathy (e.g., hemoglobin ≤ 10 g\u002FdL or platelet count \\\u003C 100,000\u002FμL, bleeding needing transfusion within 30 days, and so on).\n* Allergy to stent metal, contrat media, and antiplatelet regimens.\n* Moderate to severe hepatic dysfunction (Child-Pugh class B or C).\n* Need for oral anticoagulation therapy.\n* Current or potential pregnancy.\n* Currently treated with strong CYP3A4 inhibitors.\n* Life expectancy \\\u003C1 year.","ALL","19 Years","80 Years",{"count":84,"type":85},2312,"ESTIMATED","INTERVENTIONAL",[88],"PHASE4","DAPT de-escalation strategies to reduce bleeding include de-escalation of DAPT intensity (downgrading from potent P2Y12 inhibitor at conventional doses to either clopidogrel or reduced-dose prasugrel) or abbreviation of DAPT duration. The EASTYLE trial will evaluate a hybrid DAPT de-escalation strategy (reduced-dose ticagrelor, followed by aspirin early discontinuation) in AMI patients, compared with a conventional DAPT strategy.",[91],"Acute Myocardial Infarction",[93,94,9,95],"Ticagrelor","DAPT","Abbreviated strategy","2025-09-26",{"date":98,"type":99},"2025-10-01","ACTUAL",{"date":101,"type":99},"2023-03-27",{"date":103,"type":85},"2028-01-31",{"name":5,"class":6},1]